| Assessment Status |
Rapid Review Complete |
| HTA ID |
- |
| Drug |
Fluticasone furoate/vilanterol |
| Brand |
Relvar™ Ellipta™ |
| Indication |
For both (i) the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta-2-agonist. and (ii) for symptomatic treatment of patients with COPD with a FEV1<70% of predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy. |
| Rapid review commissioned |
10/12/2013 |
| Rapid review completed |
23/12/2013 |
| Rapid review outcome |
Full Pharmacoeconomic Evaluation not Recommended. |
